Contact
searchSearch
HMP Global
Login

News

News
High-Sensitivity Calcitonin Testing Establishes New Cutoffs for Nodal Metastasis in Medullary Thyroid Cancer
12/04/2025
Stephanie Holland
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter...
12/04/2025
Oncology
News
Dabrafenib Plus Trametinib Shows Significant Clinical Benefit in BRAF V600E-Mutated Thyroid Cancer
11/07/2025
Stephanie Holland
Results from a phase 3 trial demonstrated that dabrafenib plus trametinib significantly improved survival and response rates among patients with BRAF V600E-mutated, radioiodine-refractory thyroid cancer.
Results from a phase 3 trial demonstrated that dabrafenib plus trametinib significantly improved survival and response rates among patients with BRAF V600E-mutated, radioiodine-refractory thyroid cancer.
Results from a phase 3 trial...
11/07/2025
Oncology
News
Implications of PD-L1 Positivity for Patients With Papillary Thyroid Cancer
10/09/2025
Allison Casey
According to a retrospective, real-world analysis, PD-L1 positivity was found to be associated with multiple adverse features and an increased risk of recurrence among a cohort of Greek patients with papillary thyroid cancer.
According to a retrospective, real-world analysis, PD-L1 positivity was found to be associated with multiple adverse features and an increased risk of recurrence among a cohort of Greek patients with papillary thyroid cancer.
According to a retrospective,...
10/09/2025
Oncology
News
The Benefit of Trimodal Therapy for Anaplastic Thyroid Cancer
08/07/2025
Allison Casey
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to a retrospective...
08/07/2025
Oncology
News
Causes of Deaths Among Patients With Differentiated Thyroid Cancer
07/17/2025
Allison Casey
According to a retrospective study, a substantial proportion of deaths among patients with metastatic DTC were due to non–cancer-related causes.
According to a retrospective study, a substantial proportion of deaths among patients with metastatic DTC were due to non–cancer-related causes.
According to a retrospective...
07/17/2025
Oncology
News
Impact of Postoperative Issues on Sleep Quality Following Thyroidectomy
06/25/2025
Allison Casey
A descriptive, prospective study found a significant decrease in sleep quality after patients with thyroid cancer had undergone thyroidectomy.
A descriptive, prospective study found a significant decrease in sleep quality after patients with thyroid cancer had undergone thyroidectomy.
A descriptive, prospective study...
06/25/2025
Oncology
Conference Coverage
Neoadjuvant Pembrolizumab Plus Dabrafenib and Trametinib Improved Outcomes for Patients With BRAF-Mutated Anaplastic Thyroid Cancer
06/18/2025
Allison Casey
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a...
06/18/2025
Oncology
Conference Coverage
Neoadjuvant Pembrolizumab Plus Dabrafenib and Trametinib Improved Outcomes for Patients With BRAF-Mutated Anaplastic Thyroid Cancer
06/18/2025
Allison Casey
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a...
06/18/2025
Oncology
News
Use of Patient-Derived Organoids-Based Testing to Guide Neoadjuvant Treatment for Patients With Locally Advanced Thyroid Cancer
05/06/2025
Allison Casey
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a single arm, phase...
05/06/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use